VS Pharmtech Boosts Cancer Treatment Efficacy Without Adding Toxicity

AI Summary

South Korea's VS Pharmtech is developing an anticancer efficacy enhancer intended to improve the effectiveness of existing cancer treatments without increasing toxicity. The company, led by CEO Park Shin-young, is pursuing an approach that supports existing therapies rather than developing a new anticancer drug.

SEOUL, South Korea, Nov. 7, 2026 /PRNewswire/ — Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anticancer drugs often carry severe toxicity. Rather than developing a new anticancer drug, Park Shin-young, CEO of VS Pharmtech (https://www.vspharmtech.com/), has focused on an “anticancer efficacy enhancer” […]